![]() ![]() Continue enrollment and follow-up in the 4D-710 Phase 1/2 clinical trial for cystic fibrosis.Provide clinical data update from the 4D-310 Phase 1/2 clinical trial of 4D-310 in Fabry disease in the first half of 2023.Provide initial clinical data from the 4D-150 Phase 1/2 clinical trial for wet AMD in mid-2023. ![]() The production capacity provided by our facilities and added capabilities are designed to shorten product development timelines, reduce cost, and improve quality. Clinical trial material produced from this facility is expected to support each product candidate’s pivotal studies, and the facilities will provide a broad range of analytical capabilities, including potency assay development and validation.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |